Australia's most trusted
source of pharma news
Posted 23 April 2026 AM
Ferring Pharmaceuticals has been given the greenlight to conduct Phase 3 and 3b studies of nadofaragene firadenovec for non-muscle invasive bladder cancer (NMIBC), lining up a much larger indication for the gene therapy.
While the pharma is yet to make a submission to the TGA, the therapy was approved in the US in 2022 under the brand name Adstiladrin for the treatment of adults with high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumours.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.